Periactin

(Cyproheptadine)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Periactin is one of 201 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

200

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Mitral RegurgitationRecruiting

COVID-19Unknown status

GrowthTerminated

PediatricActive, not recruiting

StrokePreclinical

Active, not recruiting

Spinal Cord InjuryPreclinical

Active, not recruiting

Mitral RegurgitationPhase 2

Recruiting

COVID-19Phase 3

Unknown status

GrowthApproved

Terminated

PediatricApproved

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Mitral Regurgitation

NCT05469165

Q3 2030

Phase 2Active, not recruiting

COVID-19

NCT04488081

Clinical

Trials by Indication[1]

COVID-192 trials

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 3·NCT04979221·274 enrolled

Pediatric2 trials

The Use of Cyproheptadine in Pediatric Feeding Disorders

Active, not recruiting·UUniversity of Miami·Phase 4·NCT06751290·50 enrolled

Pediatric Oncology Nutrition Intervention Trial

Completed·CCorey Hawes·Phase 2/3·NCT06175273·19 enrolled

Fatigue1 trial

Mechanisms of Neuromuscular Fatigue Post Stroke

Completed·MMedical College of Wisconsin·Phase 1·NCT01688570·27 enrolled

Combination Therapy1 trial

A Study of Combination Therapy in Children With ADHD

Completed·DDouglas Sears·Phase 4·NCT01940978·99 enrolled

Spinal Cord Injury1 trial

Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury

Completed·TT. George Hornby·N/A·NCT01538693·30 enrolled

8 more indications

Mitral regurgitation1 trial

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Recruiting·LLaval University·Phase 2·NCT05469165·214 enrolled

Nausea1 trial

Noninvasive Markers of Functional Nausea in Children

Active, not recruiting·VVanderbilt University Medical Center·Phase 1·NCT03593811·42 enrolled

Alcohol Drinking1 trial

A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking

Completed·—·Phase 2·NCT01076283·14 enrolled

Growth1 trial

Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders

Terminated·MMedical College of Wisconsin·Phase 4·NCT02568007·4 enrolled

PET1 trial

Cyproheptadine as an Appetite Stimulant

Unknown status·SSt. Justine's Hospital·Phase 4·NCT01314989·20 enrolled

Alcohol Use Disorder1 trial

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Completed·KKinnov Therapeutics·Phase 2·NCT04108104·154 enrolled

Abdominal pain1 trial

A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

Terminated·UUniversity of Michigan·Phase 2·NCT01675050·4 enrolled

Stroke1 trial

Altering Activation Patterns Post-stroke

Unknown status·SShirley Ryan AbilityLab·N/A·NCT02418949·96 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PERIACTIN

NDA NDA013220

Jan 1, 1982

PERIACTIN

NDA NDA012649

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Cyproheptadine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyproheptadine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyproheptadine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013220). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Periactin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2030

Trials by Indication[1]

COVID-192 trials

Pediatric2 trials

Fatigue1 trial

Combination Therapy1 trial

Spinal Cord Injury1 trial

Mitral regurgitation1 trial

Nausea1 trial

Alcohol Drinking1 trial

Growth1 trial

PET1 trial

Alcohol Use Disorder1 trial

Abdominal pain1 trial

Stroke1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News